ZNF281 Promotes Colon Fibroblast Activation in TGFβ1-Induced Gut Fibrosis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Sep 23

PMID 36142169

Authors

Ilaria Laudadio

Alex Bastianelli

Valerio Fulci

Claudia Carissimi

Eleonora Colantoni

Francesca Palone

Roberta Vitali

Elisa Lorefice

Salvatore Cucchiara

Anna Negroni

Laura Stronati

Affiliations

Soon will be listed here.

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gastrointestinal tract. Chronic inflammation is the main factor leading to intestinal fibrosis, resulting in recurrent stenosis, especially in CD patients. Currently, the underlying molecular mechanisms of fibrosis are still unclear. ZNF281 is a zinc-finger transcriptional regulator that has been characterized as an epithelial-to-mesenchymal transition (EMT)-inducing transcription factor, suggesting its involvement in the regulation of pluripotency, stemness, and cancer. The aim of this study is to investigate in vivo and in vitro the role of ZNF281 in intestinal fibrogenesis. Intestinal fibrosis was studied in vivo in C57BL/6J mice with chronic colitis induced by two or three cycles of administration of dextran sulfate sodium (DSS). The contribution of ZNF281 to gut fibrosis was studied in vitro in the human colon fibroblast cell line CCD-18Co, activated by the pro-fibrotic cytokine TGFβ1. ZNF281 was downregulated by siRNA transfection, and RNA-sequencing was performed to identify genes regulated by TGFβ1 in activated colon fibroblasts via ZNF281. Results showed a marked increase of ZNF281 in in vivo murine fibrotic colon as well as in in vitro human colon fibroblasts activated by TGFβ1. Moreover, abrogation of ZNF281 in TGFβ1-treated fibroblasts affected the expression of genes belonging to specific pathways linked to fibroblast activation and differentiation into myofibroblasts. We demonstrated that ZNF281 is a key regulator of colon fibroblast activation and myofibroblast differentiation upon fibrotic stimuli by transcriptionally controlling extracellular matrix (ECM) composition, remodeling, and cell contraction, highlighting a new role in the onset and progression of gut fibrosis.

Citing Articles

ZNF281 Facilitates the Invasion of Cervical Cancer Cell Both In Vivo and In Vitro .

Chong Y, Zhang K, Zeng Y, Chen Q, Feng Q, Cui N Cancers (Basel). 2024; 16(21).

PMID: 39518154 PMC: 11545007. DOI: 10.3390/cancers16213717.

Inhibition of intestinal inflammation and fibrosis by Scutellaria Baicalensis georgi and Boswellia serrata in human epithelial cells and fibroblasts.

Laudadio I, Leter B, Palone F, Cucchiara S, Carissimi C, Scafa N Immun Inflamm Dis. 2024; 12(10):e70036.

PMID: 39377749 PMC: 11460024. DOI: 10.1002/iid3.70036.

Mechanism of Action and Therapeutic Implications of Nrf2/HO-1 in Inflammatory Bowel Disease.

Yuan L, Wang Y, Li N, Yang X, Sun X, Tian H Antioxidants (Basel). 2024; 13(8).

PMID: 39199256 PMC: 11351392. DOI: 10.3390/antiox13081012.

The Diagnosis of Intestinal Fibrosis in Crohn's Disease-Present and Future.

Jarmakiewicz-Czaja S, Gruszecka J, Filip R Int J Mol Sci. 2024; 25(13).

PMID: 39000043 PMC: 11241173. DOI: 10.3390/ijms25136935.

Molecular targets associated with ulcerative colitis and the benefits of atractylenolides-based therapy.

Qian H, Ye Z, Hu Y, Wu M, Chen L, Li L Front Pharmacol. 2024; 15:1398294.

PMID: 38860174 PMC: 11163078. DOI: 10.3389/fphar.2024.1398294.

References

DAlessio S, Ungaro F, Noviello D, Lovisa S, Peyrin-Biroulet L, Danese S . Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat Rev Gastroenterol Hepatol. 2021; 19(3):169-184. DOI: 10.1038/s41575-021-00543-0. View

Hahn S, Hermeking H . ZNF281/ZBP-99: a new player in epithelial-mesenchymal transition, stemness, and cancer. J Mol Med (Berl). 2014; 92(6):571-81. DOI: 10.1007/s00109-014-1160-3. View

Ahmed H, Umar M, Imran S, Javaid F, Syed S, Riaz R . TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop. Exp Mol Pathol. 2021; 124:104733. DOI: 10.1016/j.yexmp.2021.104733. View

Pieraccioli M, Nicolai S, Antonov A, Somers J, Malewicz M, Melino G . ZNF281 contributes to the DNA damage response by controlling the expression of XRCC2 and XRCC4. Oncogene. 2015; 35(20):2592-601. DOI: 10.1038/onc.2015.320. View

Finnson K, Almadani Y, Philip A . Non-canonical (non-SMAD2/3) TGF-β signaling in fibrosis: Mechanisms and targets. Semin Cell Dev Biol. 2019; 101:115-122. DOI: 10.1016/j.semcdb.2019.11.013. View

Xu F, Liu C, Zhou D, Zhang L . TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis. J Histochem Cytochem. 2016; 64(3):157-67. PMC: 4810800. DOI: 10.1369/0022155415627681. View

Henderson N, Rieder F, Wynn T . Fibrosis: from mechanisms to medicines. Nature. 2020; 587(7835):555-566. PMC: 8034822. DOI: 10.1038/s41586-020-2938-9. View

Nicolai S, Pieraccioli M, Smirnov A, Pitolli C, Anemona L, Mauriello A . ZNF281/Zfp281 is a target of miR-1 and counteracts muscle differentiation. Mol Oncol. 2019; 14(2):294-308. PMC: 6998661. DOI: 10.1002/1878-0261.12605. View

Burke J, Watson R, Murphy M, Docherty N, Coffey J, OConnell P . Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Br J Surg. 2009; 96(5):541-51. DOI: 10.1002/bjs.6577. View

10.

Ding S, Walton K, Blue R, McNaughton K, Macnaughton K, Magness S . Mucosal healing and fibrosis after acute or chronic inflammation in wild type FVB-N mice and C57BL6 procollagen α1(I)-promoter-GFP reporter mice. PLoS One. 2012; 7(8):e42568. PMC: 3411826. DOI: 10.1371/journal.pone.0042568. View

11.

Zhu Y, Zhou Q, Zhu G, Xing Y, Li S, Ren N . GSK-3β phosphorylation-dependent degradation of ZNF281 by β-TrCP2 suppresses colorectal cancer progression. Oncotarget. 2017; 8(51):88599-88612. PMC: 5687630. DOI: 10.18632/oncotarget.20100. View

12.

Rieder F, Fiocchi C, Rogler G . Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2016; 152(2):340-350.e6. PMC: 5209279. DOI: 10.1053/j.gastro.2016.09.047. View

13.

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

14.

Rieder F, Fiocchi C . Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009; 6(4):228-35. DOI: 10.1038/nrgastro.2009.31. View

15.

Ong C, Tham C, Harith H, Firdaus N, Israf D . TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies. Eur J Pharmacol. 2021; 911:174510. DOI: 10.1016/j.ejphar.2021.174510. View

16.

Cassandri M, Smirnov A, Novelli F, Pitolli C, Agostini M, Malewicz M . Zinc-finger proteins in health and disease. Cell Death Discov. 2017; 3:17071. PMC: 5683310. DOI: 10.1038/cddiscovery.2017.71. View

17.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

18.

Imai J, Yahata T, Ichikawa H, Ibrahim A, Yazawa M, Sumiyoshi H . Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice. Intest Res. 2020; 18(2):219-228. PMC: 7206341. DOI: 10.5217/ir.2019.00037. View

19.

Frankish A, Diekhans M, Jungreis I, Lagarde J, Loveland J, Mudge J . GENCODE 2021. Nucleic Acids Res. 2020; 49(D1):D916-D923. PMC: 7778937. DOI: 10.1093/nar/gkaa1087. View

20.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View